At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Oxford based Director operating in the Biotechnology space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Clive G. Brown
Directorships of Oxford Nanopore Technologies
Clive is Chief Technology Officer at Oxford Nanopore. On the Executive team, he is responsible for all of the Company’s product development activities. Clive leads the specification and design of the Company’s nanopore based sensing platform, including strand DNA/RNA sequencing and protein sensing applications with a strong focus on scientific excellence and successful adoption by the scientific community. Clive joined Oxford Nanopore from the Wellcome Trust Sanger Institute (Cambridge, UK) where he played a key role in the adoption and exploitation of ‘next generation’ DNA sequencing platforms. This involved helping to set up the world’s largest single installation of Illumina (formerly Solexa) Genome Analyzers in a production sequencing environment, initially used to pioneer the 1000 genomes project. From early 2003 he was Director of Computational Biology & IT at Solexa Ltd, where he was central to the development and commercialisation of the Genome Analyzer (GA). Solexa was sold to Illumina for $650M in early 2007 after the successful placement and adoption of 12 instruments. The Solexa technology, now commercialised by Illumina, is the market leading DNA sequencing technology driving the renaissance in DNA based discovery. He has a strong background in computer science and genetics/molecular biology and manages interdisciplinary teams including mechanical engineering, electronics, physics, surface chemistry, electrophysiology, software engineering and applications (of the technology). Clive applies modern agile management techniques to the entire product development lifecycle. Clive has also held various management and consulting positions at GlaxoWellcome, Oxford Glycosciences and other EU- and US-based organisations. He has worked at the interface between computing and science, ranging from genetics to proteomics. He holds degrees in Genetics and Computational Biology from the University of York.
Follow Clive G. Brown:
About Oxford Nanopore Technologies, Solexa: Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.
Dennis Engelke
Executive Director, Country Manager Switzerland & Austria of Jazz Pharmaceuticals
Dennis Engelke is the director of business analysis and insight at [Jazz Pharmaceuticals](https://www.crunchbase.com/organization/jazz-pharmaceuticals), an international biopharmaceutical company. Engelke holds an MBA from Uppsala University and an MBA from the University of Hamburg.
Follow Dennis Engelke:
About Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments.
Andrew Barker
Co-Founder & Director of Intelligent Ultrasound
Andrew Barker is the Chairman at Oxford Brain Diagnostics .
Follow Andrew Barker:
About Anchard Associates, Brainomix, Intelligent Ultrasound, Oxford Brain Diagnostics: Intelligent Ultrasound develops software that improves the quality, reliability, and diagnostic power of medical ultrasound.
Chris Jones
Non Executive Director & Special Advisor of MediSieve
Chris Jones joined Elasmogen as Executive Chairman in 2016.
Follow Chris Jones:
About Elasmogen, MediSieve, Mologic: MediSieve is a therapeutics company developing a platform technology for the treatment of blood-borne diseases.
Kathryn Millett
Director of Biosecu.re
Kathryn Millett is the Director of Biosecure, a company dedicated to safeguarding the bioeconomy, and strengthening biosecurity through education, training and policy advocacy.
Follow Kathryn Millett:
About Biosecu.re: Biosecu.re helps ensure a resilient, safe, and secure environments, frameworks, and processes.
Gil McVean
Co Founder & Director of Genomics
Gil McVean is Professor of Statistical Genetics at the University of Oxford and Head of Bioinformatics and Statistical Genetics at the Wellcome Trust Centre for Human Genetics. After an undergraduate training in Zoology, he obtained a PhD with Laurence Hurst in Cambridge and worked with Brian and Deborah Charlesworth in Edinburgh before joining Oxford in 2000. His research focuses on understanding the molecular and evolutionary processes that shape genetic variation in populations and the relationship between genetic variation and phenotype. He has made contributions to our understanding of areas including recombination hotspots, historical patterns of natural selection, the male mutation rate, human genetic variation, the role of HLA in complex disease and genealogical processes. He has played a leading role in the HapMap and 1000 Genomes Projects and currently works on organisms from HIV to malaria.
Follow Gil McVean:
About Genomics: Genomics plc aiming to lead the genomic transformation of healthcare.
Oliver Kessler
Founder, Medical Director and Chief Medical Officer of Orthox Ltd.
Oliver Kessler is a practising knee surgeon based in Zurich with a strong track record of biomaterials research and a focus on meniscal and cartilage repair systems and joint kinematics. He spent 6 years at Stryker Orthopaedics as Director of Orthobiologics supervising a major meniscal tissue engineering programme. He has extensive contacts within both the orthopaedic industry and the surgical community and is responsible for overseeing clinical development of Orthox’s product pipeline.
Follow Oliver Kessler:
About Orthox Ltd.: Orthox develops tissue regenerative implants that address large injuries to cartilage tissues in which early osteoarthritis may be present.
Jonathan Hollick
Managing Director of Breakpoint Therapeutics
Follow Jonathan Hollick:
About Breakpoint Therapeutics: Breakpoint Therapeutics is a company that discover and develop new anti-cancer drugs.
Mick Hunter
Chief Scientific Officer & Director of Development of Atopix Therapeutics
Dr Mick Hunter has responsibility for drug discovery and development in Atopix. He has over 28 years experience in Pharmaceutical and Biotech R&D. He has spent the past 12 years working on the discovery and development of antinflammatory and respiratory drugs. He is also Director of Discovery at Oxagen Ltd. Mick has led Atopix CRTH2 antagonist discovery and development program from concept to Phase IIb. Less Mick has experience of leading teams to identify IND candidates and managing them through early clinical development. He is familiar with regulatory environments and has managed biological pilot plants for GMP manufacture. Prior to joining Atopix, Mick held positions at Oxagen Ltd, British Biotech Pharmaceuticals (now Vernalis PLC) and at Searle Pharmaceuticals.
Follow Mick Hunter:
About Atopix Therapeutics: Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK
Sally Adams
Development Director of Scancell
Dr. Sally Adams was Head of Neurology & Virology at British Biotech and Development Director at Neures Limited before becoming an independent consultant providing drug development and management services within the biotechnology and pharmaceutical sectors, specializing in biological entities. She has worked on many complex projects over the past 25 years including anti-infective vaccines, cancer immunotherapies and an innovative stem cell treatment for visual dysfunction. Sally previously worked as a development consultant to Scancell, providing guidance on the development of SCIB1, before her appointment as Development Director in May 2014.
Follow Sally Adams:
About Scancell: Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.
Philipp Kukura
Founder and Director of Refeyn
Philipp Kukura is the Founder and Director at Refeyn.
Follow Philipp Kukura:
About Refeyn: Refeyn is specialising in label-free single molecule imaging and mass measurement.
Richard Saunders
Technical Director International Regulatory Affairs of Ortho-Clinical Diagnostics
Richard Saunders is the Technical Director International Regulatory Affairs at Ortho Clinical Diagnostics.
Follow Richard Saunders:
About Ortho-Clinical Diagnostics, Ortho-Clinical Diagnostics: Ortho Clinical Diagnostics is a company that makes in vitro diagnostics products.
